What should I know first?

Cannabis use disorder is a pattern of cannabis use that becomes difficult to control and causes significant difficulties in everyday life. Cannabis products vary greatly in composition and strength. THC is the principal intoxicating component, while products described as CBD are not equivalent to THC-containing cannabis and are not automatically risk-free.

The diagnosis does not apply to every person who uses cannabis. It concerns impaired control and consequences, not a moral judgement, a particular lifestyle or whether a product is legally available.

Signs and withdrawal symptoms

Difficulty cutting down, craving and continuing despite problems may be accompanied by sleep disruption, irritability or appetite changes when stopping. Cannabis can also affect concentration, memory and judgement; intoxication is not the same as a persistent use disorder.

Assessment

The clinician asks about frequency, product strength, other substances, sleep, daily functioning and the reasons for use. Anxiety, low mood or unusual perceptions need attention rather than an assumption that cannabis explains everything. Testing is interpreted alongside the history.

How common is it?

Cannabis exposure is much more common than a confirmed use disorder, and the two should not be counted interchangeably. Estimates depend on population, frequency, product strength and the definition used. Earlier or more frequent exposure can increase risk, but a population association does not diagnose an individual. US estimates among cannabis users are not presented here as UK population prevalence. Treatment and emergency-care figures also miss many people who never seek help.

What Causes It?

Risk reflects an interaction of exposure, individual vulnerability and circumstances. Frequent use, starting at a younger age and high-THC products can increase concern. People may use cannabis to manage distress, insomnia or social pressures, but short-term relief can reinforce repeated use without resolving the original difficulty.

Family and environmental influences also matter. Association does not mean that a single factor explains a person's experience. Care should explore what the substance does for the individual, what harms are emerging and what safer, sustainable alternatives could meet those needs.

What Do We Know About the Brain?

Cannabis affects brain processes involved in memory, attention, perception and reward. Repeated exposure can lead to adaptation, helping explain tolerance, cravings and symptoms during withdrawal. Brain effects vary with age, product composition, frequency and other health factors. Research findings describe patterns across groups, not a scan that can identify addiction in one person.

Cognitive difficulties deserve assessment, but they should not be assumed permanent or attributed entirely to cannabis without considering sleep, mood and other substances. Recovery involves both reducing substance-related harm and supporting ordinary learning and routines.

Conditions With Similar Symptoms

Anxiety disorders, depression, ADHD and primary sleep disorders can resemble or coexist with cannabis-related problems. Withdrawal-related insomnia should be distinguished from insomnia that preceded use. Recurrent severe vomiting can be associated with cannabis, but other medical causes must be considered.

Hallucinations or paranoia may occur during substance effects or reflect a separate psychotic condition. Their timing and persistence matter; a positive cannabis test does not settle the cause. Unexpectedly severe symptoms also raise concern about other substances or product contents.

Urgent symptoms require assessment rather than diagnostic assumptions.

Other Conditions That Can Occur Together

Other substance use, depression, anxiety and psychotic disorders may occur alongside cannabis use disorder. CDC describes an association between cannabis use and psychosis, especially with earlier and more frequent use; this does not establish cannabis as the sole cause in an individual.

Clinicians should assess both the substance pattern and psychiatric symptoms instead of treating one as a reason to ignore the other. Tobacco use may accompany cannabis use and deserves its own plan. Safety assessment includes driving, hazardous activities and the effects of impairment on dependents.

UK treatment and support

A GP or local drug service can help formulate a treatment plan. NICE CG51 includes psychosocial care for cannabis problems and psychological treatment for coexisting anxiety or depression. It does not establish a uniform service offer in all four UK nations.

The role of medicines

This record does not identify an established UK substitute-medicine regimen for cannabis dependence. Medicines prescribed for a separate diagnosed condition require their own indication and safety assessment. A medical cannabis prescription for another illness is not evidence that cannabis treats addiction.

What to Expect Over Time

The course varies with severity, ongoing exposure, other mental health difficulties and available support. Withdrawal can complicate early change, particularly through poor sleep and irritability, but continuing symptoms deserve reassessment rather than an automatic assumption that they are all withdrawal.

Some people improve with brief support; others need sustained care. A return to use can identify an unmet need or trigger and is a reason to adjust the plan. Improvement is measured through control, safety and functioning, not a claim that every difficulty will disappear on a fixed timetable.

Reducing everyday disruption

Discuss routines, work or study demands and a realistic plan for stressful situations. Avoid driving while impaired. Products sold as cannabis or CBD may contain unexpected ingredients; an unfamiliar product name does not establish safety.

When to seek urgent help

Severe agitation, confusion, frightening hallucinations or collapse require urgent medical assessment. If there is immediate danger, contact local emergency services. Tell clinicians about recent products and any alcohol or medicines, without delaying help because the substance is uncertain.

History

Cannabis has a long history of medicinal, cultural and recreational use. Modern discussions often place it between opposing claims that it is harmless or inevitably destructive, neither of which captures individual risk. Psychiatric classifications have also changed. DSM-5 combined the earlier abuse and dependence categories and formally recognised cannabis withdrawal, reflecting evidence that stopping after sustained use can produce a recognisable symptom pattern.

ICD-11 uses a related but different framework for harmful use, dependence and induced conditions. Contemporary research pays closer attention to product potency, age at first use and frequency. Historical observations remain useful, but older descriptions of a universal loss of motivation or a predetermined progression to other drugs should not be treated as settled explanations.

Sources and References

  1. Cannabis

    Scope: International scientific background; not UK prescribing or healthcare guidance.

  2. Understanding Your Risk for Cannabis Use Disorder

    Scope: International scientific background; not UK prescribing or healthcare guidance.

  3. Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders (2024)

    Scope: International scientific background; not UK prescribing or healthcare guidance.

  4. What Is a Substance Use Disorder? (physician review 2024-04)

    Scope: International scientific background; not UK prescribing or healthcare guidance.

  5. Cannabis: effects and risks

    Scope: United Kingdom; service delivery may differ by nation.

  6. Cannabis

    Scope: Scotland public health information.

  7. Drug addiction: getting help

    Scope: England service information; general educational principles apply more widely.

  8. Drug misuse in over 16s: psychosocial interventions — recommendations

    Scope: NICE guidance; national adoption and local implementation vary.

  9. Highlights of Changes from DSM-IV-TR to DSM-5 (2013)

    Scope: International explanatory background; not UK prescribing or service guidance.

  10. Cannabis and Mental Health

    Scope: International explanatory background; not UK prescribing or service guidance.

  11. Schizophrenia
  12. NIMH: Understanding psychosis

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top